| Manipulations of the gut microbiome alter chemotherapy-induced inflammation and behavioral side effects in female mice CV Grant, BR Loman, MT Bailey, LM Pyter Brain, Behavior, and Immunity 95, 401-412, 2021 | 62 | 2021 |
| Cytotoxicity and mechanism of action of the marine-derived fungal metabolite trichodermamide B and synthetic analogues PE Jans, AM Mfuh, HD Arman, CV Shaffer, OV Larionov, SL Mooberry Journal of natural products 80 (3), 676-683, 2017 | 38 | 2017 |
| Design, Synthesis, and Preclinical Evaluation of 4-Substituted-5-methyl-furo[2,3-d]pyrimidines as Microtubule Targeting Agents That Are Effective against Multidrug … RKV Devambatla, OA Namjoshi, S Choudhary, E Hamel, CV Shaffer, ... Journal of medicinal chemistry 59 (12), 5752-5765, 2016 | 36 | 2016 |
| Texas native plants yield compounds with cytotoxic activities against prostate cancer cells CV Shaffer, S Cai, J Peng, AJ Robles, RM Hartley, DR Powell, L Du, ... Journal of natural products 79 (3), 531-540, 2016 | 34 | 2016 |
| Triple-negative breast cancer cell line sensitivity to englerin A identifies a new, targetable subtype CV Grant, CM Carver, SD Hastings, K Ramachandran, M Muniswamy, ... Breast cancer research and treatment 177 (2), 345-355, 2019 | 18 | 2019 |
| CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells CV Grant, S Cai, AL Risinger, H Liang, BR O’Keefe, JG Doench, ... Journal of Natural Products 83 (10), 3080-3092, 2020 | 15 | 2020 |
| Voluntary wheel running ameliorates select paclitaxel chemotherapy-induced sickness behaviors and associated melanocortin signaling KA Sullivan, CV Grant, KR Jordan, SS Vickery, LM Pyter Behavioural Brain Research 399, 113041, 2021 | 12 | 2021 |
| Paclitaxel chemotherapy disrupts behavioral and molecular circadian clocks in mice KA Sullivan, CV Grant, KR Jordan, K Obrietan, LM Pyter Brain, behavior, and immunity 99, 106-118, 2022 | 9 | 2022 |
| Yuanhuacine Is a Potent and Selective Inhibitor of the Basal-Like 2 Subtype of Triple Negative Breast Cancer with Immunogenic Potential CS Fermaintt, T Peramuna, S Cai, L Takahashi-Ruiz, JN Essif, CV Grant, ... Cancers 13 (11), 2834, 2021 | 9 | 2021 |
| A novel targeted approach to delineate a role for estrogen receptor-β in ameliorating murine mammary tumor-associated neuroinflammation CV Grant, KLG Russart, LM Pyter Endocrine 75 (3), 949-958, 2022 | 6 | 2022 |
| Mammary tumors alter the fecal bacteriome and permit enteric bacterial translocation BR Loman, KLG Russart, CV Grant, AJ Lynch, MT Bailey, LM Pyter BMC cancer 22 (1), 1-13, 2022 | 5 | 2022 |
| A novel CXCR4 pathway is required for migration of metastatic breast cancer cells J Freed, CV Shaffer, CC Moore Cancer Research 75 (15 Supplement), 4043-4043, 2015 | 3 | 2015 |
| Abstract P5-04-18: Extracts derived from fungi and plants demonstrate specificity for subtyptes of triple negative breast cancer CV Shaffer, S Cai, A Perez, AL Risinger, L Du, BR O'Keefe, RH Cichewicz, ... Cancer Research 76 (4 Supplement), P5-04-18-P5-04-18, 2016 | 1 | 2016 |
| The gut microbiome significantly contributes to the development of chemotherapy-associated, brain-mediated side effects CV Grant, BR Loman, MT Bailey, LM Pyter Brain, Behavior, and Immunity 98, 19, 2021 | | 2021 |
| VOLUNTARY EXERCISE ATTENUATES LONG-TERM CHEMOTHERAPY-ASSOCIATED CACHEXIA AND MODULATES CENTRAL AND HORMONAL FOOD-INTAKE REGULATION IN MICE CV Grant, KA Sullivan, S Vickery, KR Jordan, LM Pyter PSYCHOSOMATIC MEDICINE 83 (7), A65-A65, 2021 | | 2021 |
| Identification of new molecular liabilities of a subset of triple-negative breast cancers through the investigation of englerin A CV Grant, CM Carver, SD Hastings, AL Risinger, JA Beutler, SL Mooberry Cancer Research 79 (13 Supplement), 2143-2143, 2019 | | 2019 |
| Drug Discovery for Subtypes of Triple-Negative Breast Cancer CV Grant The University of Texas Health Science Center at San Antonio, 2019 | | 2019 |
| Characteristics of triple negative breast cancer that result in sensitivity to englerin A CV Shaffer, AL Risinger, JA Beutler, SL Mooberry Cancer Research 78 (13 Supplement), 2908-2908, 2018 | | 2018 |
| Abstract P2-13-01: Differential efficacies of DNA damaging agents in basal-like TNBC subtypes CV Shaffer, AJ Robles, AL Risinger, SL Mooberry Cancer Research 78 (4 Supplement), P2-13-01-P2-13-01, 2018 | | 2018 |
| Identifying specific inhibitors of triple-negative breast cancer subtypes AJ Robles, S Cai, L Du, CV Shaffer, T Grkovic, AL Risinger, BR O'Keefe, ... Planta Medica 82 (S 01), P477, 2016 | | 2016 |
